Assessment of prognosis and response
| Baseline IWG-MRT prognostic risk group . | rIFNα duration, y . | IWG-MRT response type . | Histologic bone marrow response? (yes/no) . | Spleen size before therapy, cm . | Spleen size at last follow-up, cm . | JAK2V617F (initial), % . | JAK2V617F (final), % . | Molecular response§ . |
|---|---|---|---|---|---|---|---|---|
| Low* | 7.6 | CR | Yes | 2 | 0 | ND | ND | None |
| Low | 5.2 | PR | No BM follow-up | 1 | 0 | ND | NA | NA |
| Low | 7.8 | PR | No | 0 | 0 | 9.7 | 14.3 | None |
| Low | 1.8 | PR | Yes | 12 | 0 | 33.2 | 38.0 | None |
| Low | 2.3 | PR | No | 16 | 0 | 75.4 | 52.0 | Partial |
| Low | 0.5† | PR | No | 2 | 0 | 20.5 | 18.3 | None |
| Low* | 4.7 | CI | No | 10 | 0.5 | 34.9 | 29.9 | None |
| Low | 0.8 | SD | No | 11 | 10 | 85.8 | 87.1 | None |
| Low* | 15.0 | SD | No | 7 | 0 | ND | ND | None |
| Low | 2.0‡ | SD | No | 2 | 0 | ND | ND | None |
| Low | 3.2 | PD | No | 7 | 11 | 2.0 | 18.0 | None |
| Intermediate-1 | 4.5 | CR | Yes | 3 | 0 | 10.7 | 5.3 | Partial |
| Intermediate-1 | 4.5 | PR | No | 0 | 0 | 45.6 | 24.1 | None |
| Intermediate-1 | 3.3† | PR | Yes | 3 | 0 | 10.1 | 8.0 | None |
| Intermediate-1 | 2.9 | SD | No BM follow-up | 24 | 16 | 88.1 | 89.0 | None |
| Intermediate-1* | 5.4 | PD | No | 16 | 20 | ND | ND | None |
| Intermediate-1* | 2.4† | PD | No | 32 | 24 | 64.2 | 50.4 | None |
| Baseline IWG-MRT prognostic risk group . | rIFNα duration, y . | IWG-MRT response type . | Histologic bone marrow response? (yes/no) . | Spleen size before therapy, cm . | Spleen size at last follow-up, cm . | JAK2V617F (initial), % . | JAK2V617F (final), % . | Molecular response§ . |
|---|---|---|---|---|---|---|---|---|
| Low* | 7.6 | CR | Yes | 2 | 0 | ND | ND | None |
| Low | 5.2 | PR | No BM follow-up | 1 | 0 | ND | NA | NA |
| Low | 7.8 | PR | No | 0 | 0 | 9.7 | 14.3 | None |
| Low | 1.8 | PR | Yes | 12 | 0 | 33.2 | 38.0 | None |
| Low | 2.3 | PR | No | 16 | 0 | 75.4 | 52.0 | Partial |
| Low | 0.5† | PR | No | 2 | 0 | 20.5 | 18.3 | None |
| Low* | 4.7 | CI | No | 10 | 0.5 | 34.9 | 29.9 | None |
| Low | 0.8 | SD | No | 11 | 10 | 85.8 | 87.1 | None |
| Low* | 15.0 | SD | No | 7 | 0 | ND | ND | None |
| Low | 2.0‡ | SD | No | 2 | 0 | ND | ND | None |
| Low | 3.2 | PD | No | 7 | 11 | 2.0 | 18.0 | None |
| Intermediate-1 | 4.5 | CR | Yes | 3 | 0 | 10.7 | 5.3 | Partial |
| Intermediate-1 | 4.5 | PR | No | 0 | 0 | 45.6 | 24.1 | None |
| Intermediate-1 | 3.3† | PR | Yes | 3 | 0 | 10.1 | 8.0 | None |
| Intermediate-1 | 2.9 | SD | No BM follow-up | 24 | 16 | 88.1 | 89.0 | None |
| Intermediate-1* | 5.4 | PD | No | 16 | 20 | ND | ND | None |
| Intermediate-1* | 2.4† | PD | No | 32 | 24 | 64.2 | 50.4 | None |